The efficacy and safety of levofloxacin 750 mg (Hileflox) in the treatment of chronic prostatitis

Abstract

Chronic prostatitis is the most common urological disease in men aged 20 to 50 years. Chronic bacterial prostatitis occurs in 5–10 % of cases. The aim of the study was to determine the efficacy and safety of Hileflox (levofloxacin) in chronic bacterial prostatitis in a dosage of 750 mg per day for 10 days. The study involved 40 patients with chronic bacterial prostatitis. Results. National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) scores were decreased by 72 %, which is characterized as a distinct clinical effect. Quality of life has changed on average from 4.64 to 1.46 points, which was 68 %. Results of uroflowmetry before and after treatment showed a positive trend. According to the benchmark survey of microbiological eradication of the pathogen was found in 36 (90 %) patients. In 4 patients was recorded persistence of previously identified pathogens in diagnostically significant titre. Side effects were observed in 3 (7.5 %) patients. Hileflox (levofloxacin) 750 mg course of 10 days showed marked clinical (87.5 %) and bacterial (90 %) effective in chronic bacterial prostatitis. Necessary to conduct further analysis to determine the duration of relapse-free interval.